Target intelligence / Profile preview

Unfolded or misfolded client protein

Molecular classification
Other (these are unstructured or partially structured polypeptides rather than specific molecular families like enzymes, receptors, or channels)
01

Overview

Unfolded or misfolded client proteins are polypeptides that have failed to achieve or maintain their proper three-dimensional (native) conformation, either due to mutations, cellular stress, or errors in folding pathways[7][4][1]. These proteins are recognized by molecular chaperones (such as Hsp70, Hsp90, and GroEL), which attempt to refold them or direct them for degradation, thus maintaining cellular proteostasis[3][1][5]. Accumulation of such proteins triggers the cellular unfolded protein response (UPR) and can lead to toxic aggregation implicated in neurodegenerative and protein misfolding diseases[7][1][5]. While molecules that modulate chaperone activity or proteostasis pathways are being developed as therapeutics, unfolded/misfolded client proteins themselves are not direct, tractable drug targets but rather the consequence or substrate within these pathways[1][4][5]. This entry describes a *category* of substrates within the protein quality control system, and not a specific, standardized molecular entity.

Other names
Misfolded proteinUnfolded proteinAberrant proteinNon-native polypeptideClient protein (in context of chaperones)
02

Mechanism of action

Stabilization of folding intermediates Prevention of aggregation Enhancement of degradation of misfolded proteins Modulation of chaperone activity

03

Biological functions

Protein homeostasis (proteostasis)Protein quality controlSubstrate for chaperonesProtein degradation (via proteasome or autophagy)Sometimes toxic gain of function (in amyloidoses, prion diseases)
04

Disease associations

Neurodegenerative diseaseProtein misfolding disorders (e.g., amyloidosis, prion disease)CancerCystic fibrosisOther diseases involving proteostasis imbalance
05

Safety considerations

Off-target effects from global inhibition or activation of chaperonesAccumulation of toxic protein aggregates if proteostasis is disruptedBroad impact on normal protein turnover and essential cell functions
06

Interacting drugs

Indirectly: Chaperone modulators (e.g., geldanamycin targets Hsp90, not the misfolded protein itself)

2 more in the full profile.

07

Biomarkers

Accumulation of specific misfolded or aggregated proteins (e.g., amyloid-beta, tau, alpha-synuclein)Elevated unfolded protein response markers (UPR pathway activation)

Beyond the preview

Go deeper on Unfolded or misfolded client protein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unfolded or misfolded client protein.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call